ArticleBiomaterials2026
Engineered muscle drives bone repair and functional healing after composite musculoskeletal injury.
Article in Biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Composite lower extremity injuries, characterized by open bone fractures with soft tissue damage, frequently result in delayed or failed fracture union, chronic pain and long-term disability. Standard clinical care overlooks the muscle as a critical driver of composite tissue healing, and current regenerative approaches fail to fully restore physical function. This study explores a muscle-driven approach to promote coordinated regeneration across both muscle and bone tissue. An engineered muscle (EM) composed of cell-laden nanofibrillar patterned scaffolds, was transplanted into the injured muscle in a mouse model of composite injury. EM constructs of either primary myoblasts or differentiated myotubes significantly improved healing outcomes and functional recovery compared to untreated controls. Myoblast-EM treatment led to accelerated tibial union, increased early bone mineral density, and faster restoration of symmetrical limb loading, along with enhanced single muscle fiber contractile power and velocity. Myotube-EM treatment yielded complimentary gains, including increased muscle cross-sectional area and whole-muscle force production. Importantly, all EM-treated animals exhibited higher survival rates and reduced limb morbidity. Notably, the superior functional outcomes observed with Myoblast EMs may be attributed to greater engraftment and in vivo differentiation of transplanted myogenic cells into mature myofibers. These findings introduce a paradigm-shifting regenerative strategy in which targeted muscle therapy drives systemic musculoskeletal repair, challenging conventional compartmentalized treatment models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.